Hangzhou Tigermed Consulting Co., Ltd Share Price
Equities
300347
CNE100001KV8
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.65 CNY | +3.06% |
|
+4.19% | +15.78% |
| 01-30 | Tigermed Consulting Forecasts Upto 204% Jump in 2025 Profit; Shares Rise 8% | MT |
| 01-29 | Hangzhou Tigermed Consulting sees 2025 net profit up 105-204% Y/Y | RE |
| Capitalization | 53.96B 7.78B 6.58B 6.03B 5.71B 10.61B 705B 11.09B 70.11B 27.76B 339B 29.16B 28.56B 1,221B | P/E ratio 2025 * |
45.8x | P/E ratio 2026 * | 40.8x |
|---|---|---|---|---|---|
| Enterprise value | 52.99B 7.64B 6.46B 5.92B 5.61B 10.42B 692B 10.89B 68.85B 27.26B 333B 28.64B 28.05B 1,199B | EV / Sales 2025 * |
7.7x | EV / Sales 2026 * | 6.75x |
| Free-Float |
72.37% | Yield 2025 * |
0.74% | Yield 2026 * | 0.74% |
| 1 day | +3.06% | ||
| 1 week | +4.19% | ||
| Current month | +4.19% | ||
| 1 month | +11.31% | ||
| 3 months | +11.86% | ||
| 6 months | -0.53% | ||
| Current year | +15.78% |
| 1 week | 60.2 |  | 66.43 |
| 1 month | 55.93 | | 66.47 |
| Current year | 55.93 | | 66.47 |
| 1 year | 41.61 | | 71.9 |
| 3 years | 36.12 | | 130 |
| 5 years | 36.12 | | 209.41 |
| 10 years | 14.2 | | 209.41 |
| Manager | Title | Age | Since |
|---|---|---|---|
Xiao Chun Cao
CEO | Chief Executive Officer | 56 | - |
Hao Wu
PSD | President | 59 | 31/12/2019 |
Cheng Cheng Yang
DFI | Director of Finance/CFO | 52 | 20/10/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Xiao Chun Cao
BRD | Director/Board Member | 56 | 31/12/2004 |
Bing Hui Zhang
CHM | Chairman | 62 | 27/04/2020 |
Xiao Ping Ye
CHM | Chairman | 63 | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.06% | +4.19% | +30.57% | -42.21% | 7.78B | |
| -0.19% | -1.49% | -15.63% | -7.11% | 46.82B | |
| +1.99% | +3.98% | +54.64% | +44.35% | 39.16B | |
| +1.15% | +4.76% | +26.41% | +44.46% | 32.9B | |
| +3.61% | -18.54% | -10.70% | -19.29% | 31.8B | |
| +1.39% | +0.56% | +123.75% | +272.81% | 18.85B | |
| +0.14% | -6.94% | +50.16% | +133.97% | 15.27B | |
| Average | +1.59% | -0.72% | +37.03% | +61.00% | 27.51B | |
| Weighted average by Cap. | +1.42% | -1.31% | +27.38% | +47.32% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 6.88B 992M 840M 770M 729M 1.35B 89.88B 1.42B 8.94B 3.54B 43.27B 3.72B 3.64B 156B | 7.84B 1.13B 957M 877M 830M 1.54B 102B 1.61B 10.19B 4.03B 49.28B 4.24B 4.15B 177B |
| Net income | 1.21B 175M 148M 136M 129M 239M 15.86B 250M 1.58B 625M 7.64B 657M 643M 27.49B | 1.16B 167M 142M 130M 123M 228M 15.16B 239M 1.51B 597M 7.3B 628M 615M 26.28B |
| Net Debt | -971M -140M -118M -109M -103M -191M -12.67B -200M -1.26B -499M -6.1B -525M -514M -21.96B | -1.06B -153M -130M -119M -113M -209M -13.9B -219M -1.38B -548M -6.69B -575M -564M -24.09B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/02/26 | 65.65 ¥ | +3.06% | 17,501,220 |
| 05/02/26 | 63.70 ¥ | -1.91% | 11,830,290 |
| 04/02/26 | 64.94 ¥ | +2.75% | 16,977,250 |
| 03/02/26 | 63.20 ¥ | +4.97% | 16,469,970 |
| 02/02/26 | 60.21 ¥ | -4.44% | 17,696,500 |
End-of-day quote Shenzhen S.E., February 05, 2026
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 300347 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition